Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
RPE65 encodes the retinal pigment epithelium-specific isomerohydrolase essential for the regeneration of 11-cis-retinol in the visual cycle. Biallelic loss-of-function or hypomorphic variants in RPE65 cause autosomal recessive severe early-childhood-onset retinal dystrophy, presenting in infancy with visual impairment and nyctalopia. The disorder follows an autosomal recessive inheritance pattern with compound heterozygous or homozygous variants required for disease manifestation.
Genetic analyses have identified multiple unrelated probands with RPE65-associated EOSRD: 10 patients with compound heterozygous or homozygous RPE65 mutations (PMID:15288992), 8 Indian patients with homozygous null alleles among 220 cases screened (PMID:38323530), and 46 probands detected in a cohort of 153 LCA/EOSRD patients by high-throughput array and sequencing (PMID:18055820). In a Chinese family, the patient harbored c.1590C>A (p.Phe530Leu) together with c.1243+2T>A, segregating in trans (PMID:25383945). Carriers are asymptomatic, consistent with recessive inheritance.
The RPE65 variant spectrum comprises >70 pathogenic alleles: missense substitutions (e.g., p.Arg91Trp, p.Tyr368His), loss-of-function changes including frameshifts and nonsense mutations, and splice-site defects like IVS1+5G>A. Recurrent alleles such as IVS1+5G>A have been observed across populations. Pathogenic allele frequency among LCA/EOSRD cohorts ranges from 3–16% (PMID:34281261).
Functional studies definitively establish RPE65 as the visual cycle isomerohydrolase. Recombinant RPE65 catalyzes conversion of all-trans-retinyl esters to 11-cis-retinol (PMID:16116091), and mutations of iron-coordinating residues or missense variants abolish activity (PMID:16150724). Rpe65–/– and knock-in mouse models recapitulate the human rod-cone dystrophy with absent autofluorescence, impaired electroretinograms, and photoreceptor loss (PMID:11528395, PMID:25972377).
Gene therapy and rescue experiments demonstrate therapeutic potential. Lentiviral or AAV-mediated Rpe65 gene transfer in knockout mice restores cone survival and ERG responses (PMID:17032058). In patients treated with voretigene neparvovec, OCT shows rapid morphological rescue of the fovea and improved central sensitivity (PMID:34289237). Chemical chaperones and low-temperature studies further rescue partial-function mutants (PMID:24849605).
Collectively, the robust genetic and experimental concordance fulfills ClinGen criteria for a Definitive gene–disease association. Early molecular diagnosis of RPE65 variants is critical for patient stratification and eligibility for gene replacement therapy.
Key Take-home: Biallelic pathogenic RPE65 variants reliably predict severe early-childhood-onset retinal dystrophy and identify candidates for effective gene augmentation therapy.
Gene–Disease AssociationDefinitiveOver 60 unrelated probands with biallelic RPE65 variants segregating in autosomal recessive families; extensive concordant functional and animal model data Genetic EvidenceStrongMultiple cohorts reporting 10 EOSRD patients (PMID:15288992), 8 Indian cases (PMID:38323530), and 46 probands from 153 LCA/EOSRD patients (PMID:18055820) with biallelic pathogenic variants Functional EvidenceStrongBiochemical assays defining RPE65 as the isomerohydrolase (PMID:16116091), knockout/knock-in mouse models reproducing human disease (PMID:11528395, PMID:25972377), and successful gene therapy rescue experiments (PMID:17032058) |